Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen
utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined
with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to
65 years with poor prognosis CD 20 Diffuse Large B-Cell lymphoma